Current Fellows in the Integrative Tumor Epidemiology Branch
Mustapha Abubakar, M.D., Ph.D. – Postdoctoral Fellow
Mustapha Abubakar, M.D., Ph.D., joined the Integrative Tumor Epidemiology Branch (ITEB) as a postdoctoral fellow in June 2017. Dr. Abubakar earned his medical degree from Bayero University, Kano, Nigeria in 2006. He trained in general pathology from 2009-2011 in the Department of Pathology, Aminu Kano Teaching Hospital, Nigeria. In 2012, he received his M.Sc. in epidemiology from the Imperial College London, United Kingdom, and obtained his Ph.D. in molecular epidemiology from the University of London’s Institute of Cancer Research (ICR), London in 2017. During his doctoral studies, Dr. Abubakar worked under the direction of Professors Montserrat García-Closas, Anthony Swerdlow, and Mitch Dowsett to develop a digital pathology protocol for the high-throughput scoring of KI67 in breast cancer tissue microarrays and investigate etiological and prognostic heterogeneity among breast cancer subtypes defined by KI67 and other immunohistochemical markers. In DCEG, he is working with Gretchen Gierach, Ph.D., M.P.H., Deputy Chief and senior investigator, ITEB, to conduct molecular epidemiological studies that evaluate the relationship between histopathological characteristics of breast tissues with radiologically determined mammographic density and breast cancer risk. He is also working with Montserrat García-Closas, M.D., Dr.P.H., Deputy Director, DCEG, and Xiaohong Rose Yang, Ph.D., M.P.H., senior investigator ITEB, to conduct molecular epidemiological studies of breast cancer subtypes in different populations.
Mengmeng Jia, M.D. – Predoctoral Fellow
Mengmeng Jia, M.D., joined the Integrative Tumor Epidemiology Branch (ITEB) as a predoctoral fellow in October 2018. Dr. Jia earned her M.D. in preventive medicine from Shanghai Jiao Tong University, China, in 2015. She is currently pursuing her Ph.D. in cancer epidemiology at the Chinese Academy of Medical Sciences and Peking Union Medical College. Dr. Jia’s research focuses on the screening and early detection of breast cancer and evaluation of different screening modalities, especially in resource-limited areas.
Dr. Jia works with Gretchen Gierach, Ph.D., M.P.H., Deputy Chief and senior investigator, ITEB, to conduct molecular epidemiologic studies of breast density and breast cancer.
Michael Kebede B.S. – Postbaccalaureate Fellow
Michael Kebede, B.S, joined the Integrative Tumor Epidemiology Branch (ITEB) in September 2018 as a postbaccalaureate fellow, while pursuing an M.P.H. in epidemiology from George Washington University (GWU), Washington, DC. Prior to joining ITEB, Mr. Kebede graduated from GWU in 2017 with a bachelor’s degree in exercise science with a pre-med concentration. While earning his M.P.H., he worked as a departmental graduate teaching assistant for the GWU Exercise and Nutrition Science department, where he taught anatomy and physiology in a laboratory and nutrition science. More recently, he worked as a summer intern in the Clinical Genetics Branch (CGB) with Shahinaz Gadalla, M.D., Ph.D., Earl Stadtman Investigator, and Rotana Alsaggaf, Ph.D., M.S., postdoctoral fellow, on a study of myotonic dystrophy and cancer—work that he is continuing for his master’s thesis. Following this, he spent one month at the World Health Organization completing an influenza surveillance internship for which he was selected. In ITEB, he is working under the mentorship of Maria Teresa Landi, M.D., Ph.D., senior investigator, studying the etiology and epidemiology of lung cancer in never smokers. Mr. Kebede’s primary research interests include the epidemiology and quantitative analysis of chronic diseases including cancer.
Shu-Hong Lin, Ph.D., M.S. – Postdoctoral Fellow
Shu-Hong Lin, Ph.D., M.S., joined the Integrative Tumor Epidemiology Branch (ITEB) as a postdoctoral fellow in January 2018. He earned his bachelor’s degree in veterinary medicine from National Taiwan University in 2005 and received an M.S. degree in veterinary biosciences from the Ohio State University in 2012. In 2018, he graduated with a Ph.D. in cancer biology with an area of concentration in biostatistics, bioinformatics and systems biology from the University of Texas Graduate School of Biomedical Sciences. Dr. Lin's doctoral research focused on identifying genomic and transcriptomic markers related to tumor progression in colorectal adenomas using next-generation sequencing. He also studied circulating biomarkers predictive of outcomes in non-invasive bladder cancer. In DCEG, he works with Mitchell Machiela, Sc.D., M.P.H., Earl Stadtman Tenure-Track Investigator, ITEB, to explore associations among genetic mosaicism, environmental factors, and cancer risk.
Parichoy Pal Choudhury, Ph.D. – Research Fellow
Parichoy Pal Choudhury, Ph.D., joined the Integrative Tumor Epidemiology Branch (ITEB) and the Biostatistics Branch (BB) of DCEG as a research fellow in 2019. He earned his bachelor and master degrees in statistics from the Indian Statistical Institute (2008 and 2010, respectively) and a Ph.D. in biostatistics from the Johns Hopkins Bloomberg School of Public Health in 2016. Dr. Pal Choudhury’s doctoral research focused on scientific and etiological questions using multiple data sources in scenarios where a single data source does not suffice. He continued his postdoctoral research with Dr. Nilanjan Chatterjee at Johns Hopkins, with a major focus on developing methods and software for independent validation of risk prediction models in prospective cohort studies that employ complex two-phase sampling. In DCEG, Dr. Pal Choudhury continues his research on risk prediction methods—specifically, studying the heterogeneity of risk factor associations across breast cancer subtypes and developing and validating subtype specific risk prediction models among women of both European and non-European ancestries. He is working under the mentorship of Montserrat García-Closas, M.D., Dr.P.H., DCEG Deputy Director and ITEB Acting Chief. He is also working on developing and validating models for predicting risk of mortality using data from the NIH-AARP Diet and Health Study and the Prostate, Lung, Colorectal, Ovarian Cancer Screening Trial.
Sally Lilian Yepes Torres, Ph.D., M.Sc. – Postdoctoral Fellow
Sally Yepes, M.Sc., Ph.D., joined the Integrative Tumor Epidemiology Branch (ITEB) and the Clinical Genetics Branch (CGB) as a postdoctoral fellow in May 2018. Dr. Yepes has a B.S. in biology, an M.Sc. in human genetics; she received her Ph.D. in biology in 2016 from the Universidad de los Andes in Bogotá, Colombia. Her research interests focus on cancer genomics, in particular on the generation of knowledge from a data-driven perspective, and application of methodological frameworks from the statistical genomics, bioinformatics and elements of systems biology. In DCEG, she is working under the mentorship of Xiaohong Rose Yang, Ph.D., M.P.H., senior investigator, ITEB, and Alisa Goldstein, Ph.D., senior investigator, CGB, to identify and further investigate cancer susceptibility genes in familial melanoma and chordoma using integrative analyses of next-generation sequencing and other ‘omics data.
Wei Zhao, Ph.D. – Postdoctoral Fellow
Wei Zhao, Ph.D., joined the Integrative Tumor Epidemiology Branch (ITEB) as a postdoctoral fellow in November 2018. Dr. Zhao earned her Ph.D. in bioinformatics from the University of North Carolina at Chapel Hill under the supervision of Dr. Chuck Perou in 2014. Her doctoral research focused on characterization of the genomic and clinical heterogeneity of breast cancer subtypes using deep- sequencing and microarray. Prior to joining NCI, Dr. Zhao conducted postdoctoral training in the Department of Systems Biology in MD Anderson Cancer Center for four years. Working with Dr. Gordon Mills and Dr. Han Liang, she identified predictive molecular markers and drug targets for rational combinatorial therapy in gynecologic cancers, and developed computational tools for analysis of proteomic data. In ITEB, Dr. Zhao is working with Maria Teresa Landi, Ph.D., M.D., senior investigator, to investigate the etiology and progression of lung cancer in never smokers through a comprehensive genomic analysis and clinical and epidemiologic assessment.